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mann).Clinical research includes a wide range of study designs from focused observational studies to complex
interventional studies with multiple study arms, treatment and assessment events, and specimen pro-
curement procedures. Participant characteristics from case report forms need to be integrated with
molecular characteristics from mechanistic experiments on procured specimens. In order to capture
and manage this diverse array of data, we have developed the Ontology-Based eXtensible data model
(OBX) to serve as a framework for clinical research data in the Immunology Database and Analysis Portal
(ImmPort). By designing OBX around the logical structure of the Basic Formal Ontology (BFO) and the
Ontology for Biomedical Investigations (OBI), we have found that a relatively simple conceptual model
can represent the relatively complex domain of clinical research. In addition, the common framework
provided by BFOmakes it straightforward to develop data dictionaries based on reference and application
ontologies from the OBO Foundry.
 2010 Elsevier Inc. All rights reserved.1. Introduction
The US National Institutes of Health are interested in maximiz-
ing the return on the public investment in biomedical research.
This desire has led many institutes to develop policies that encour-
age sharing of data generated from research supported by this pub-
lic funding. In this regard, the National Institute of Allergy and
Infectious Disease (NIAID) has supported a number of bioinformat-
ics initiatives designed to provide the infrastructure to capture and
manage research data for re-use and re-analysis. The Bioinformat-
ics Integration Support Contract (BISC) was awarded to develop a
long-term sustainable archive of data generated by the 1500
investigators supported by the Division of Allergy, Immunology
and Transplantation (DAIT). DAIT investigators conduct a wide
range of research program types, including basic research of im-
mune system function, translational research to determine the
underlying mechanisms of immune system disease and response
to infection, and clinical trials to evaluate the safety, toxicity, efﬁ-
cacy and mechanisms of immune disease therapies and vaccina-
tion strategies. More recently, the National Center for Researchll rights reserved.
dical Informatics, Division of
in Pathology, Department of
Harry Hines Blvd., Dallas, TX
tern.edu (R.H. Scheuermann).
ermann.html (R.H. Scheuer-Resources (NCRR) has developed the Clinical and Translational Sci-
ence Award (CTSA) program [1], ‘‘to improve human health by
transforming the research and training environment to enhance
the efﬁciency and quality of clinical and translational research”.
At many CTSA institutions, comprehensive clinical research infor-
mation systems are being developed for the electronic capture
and use of clinical and translational research data at an enterprise
level (e.g., [2,3]).
Through the BISC project, we have developed the Immunol-
ogy Database and Analysis Portal (ImmPort; www.immport.org)
as a web-based public resource to support not only the archiving
of these valuable data sets, but also to support their integration
with the biological knowledge contained in other public data
repositories (e.g., GenBank, UniProt, the Immune Epitope Data-
base) and their analysis using state-of-the-art data mining ana-
lytical tools. One of the biggest challenges in ImmPort design
is how best to manage the data derived from the wide range
of different experiment methodologies being used by DAIT-
funded investigators, which includes everything from gene
expression and SNP genotyping microarrays up through clinical
trials, as well as methodologies that are somewhat unique to
the immunology research domain (e.g., ﬂow cytometry and ELI-
SPOT). And so we have adopted a general strategy for database
development in which our database structure is designed around
the general features of any biomedical investigation, rather than
based on experimental features that might be methodology
speciﬁc.
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to ensure that the data and analytical infrastructure is maximally
interoperable with other external databases and bioinformatics re-
sources. Thus ImmPort has been an active participant and early
adopter of many data standards development initiatives, including
the development of minimum data standards like MIFlowCyt [4]
and MIGen through the MIBBI consortium [5] and ontology stan-
dards like the Ontology for Biomedical Investigations (OBI) through
the Open Biomedical Ontology (OBO) Foundry consortium [6].
In the development of a database support infrastructure for
clinical research data in ImmPort, several related clinical data stan-
dards were evaluated for potential use. The Clinical Data Inter-
change Standards Consortium (CDISC, www.cdisc.org) is a global
multi-disciplinary organization focused on the development of a
set of clinical data standards to facilitate global clinical trial data
interoperability and exchange [7,8]. CDISC leads several ongoing
projects to develop standards for representation of the study de-
signs and data elements of biomedical investigations, particularly
clinical trials. These standards include the Study Data Tabulation
Model (SDTM) for submitting clinical trial data to the FDA, the Bio-
medical Research Integrated Domain Group (BRIDG) model for
clinical trials [9,10], and the Clinical Data Acquisition Standards
Harmonization (CDASH) project for deﬁning data elements that
can be assembled into case report forms (CRFs). Because the CDISC
standards have been developed to support information about
ongoing clinical studies, they are not completely aligned with the
needs of the ImmPort system, which is largely concerned with
the results of studies and making study data available for data
re-use and re-analysis. Therefore, ImmPort does not need to repre-
sent the administrative and regulatory aspects of a study that are
important components of the CDISC standards. The SDTM stan-
dard, although it covers many of the data elements required by
ImmPort, is a data transport standard based on SAS transport ﬁles
and is therefore not a model for a data repository designed for data
retrieval and integration with other reference data. CDASH pro-
vides many elements for modeling clinical encounters, but is
incomplete for ImmPort’s purposes because it does not model a
study’s schedule of events and does not support placement of clin-
ical encounters on a study time line. The BRIDG model provides
extensive support for monitoring the execution of the study proto-
col [9,10], which is also not needed for ImmPort. Finally, none of
the CDISC models currently offer signiﬁcant support for analysis
of study data and the results derived from this analysis, and none
offer signiﬁcant support for the mechanistic studies being per-
formed with specimens derived from study subject participants.
Through this work, we have considered how minimum data
standards and ontology structures might be utilized to help inform
the design of databases. It is important to be clear about the dis-
tinction between ontologies and conceptual models. Well-formu-
lated ontologies are designed to describe universal classes of
entities in reality and how these classes invariably relate to each
other. The structure of ontologies should not be context dependent.
In contrast, conceptual models which describe the entities and the
relationships among the entities are focused on supporting in-
stance-level data in which speciﬁc representatives of entity classes
are described together with the characteristics that distinguish
individuals from each other within the class. Thus, conceptual
models need to be able to capture and integrate instance-level
characteristics and context dependencies.
In the study reported here, we have attempted to investigate
whether it would be possible to integrate these two components
of knowledge representation in such a way as to leverage the
class-level structural characteristics provided by a set of well-for-
mulated reference ontologies as an underlying common frame-
work that could then be extended in a consistent fashion to
incorporate the instance-speciﬁc details. We have speciﬁcally ap-plied this strategy to the representation of clinical research data,
including the study design components found in clinical protocols,
clinical assessment results captured in case report forms and labo-
ratory results obtained from the evaluation of derived human spec-
imens. The end result is the Ontology-Based eXtensible (OBX) data
model.2. Methods and results
In this section, the general framework of OBX model, the com-
ponents of the OBX model (biomaterial transformation, assay, data
transformation, composite process and study design.) and the
physical database implementation of the OBXmodel are presented.2.1. General framework
Two reference ontologies were chosen as the foundation for
OBX design – the Basic Formal Ontology (BFO) and the Ontology
for Biomedical Investigation (OBI). The BFO (http://www.ifomi-
s.org/bfo) was originally conceived of by Smith and Grenon as
an upper level ontology that could serve as a framework to sup-
port the development of domain-speciﬁc ontologies for scientiﬁc
research [11]. The BFO structure is based on the central dichot-
omy between objects (continuants) and processes (occurrents),
reﬂecting their distinct relationships with time. Continuants en-
dure through time and retain some notion of their identity even
while undergoing various kinds of changes. Occurrents unfold in
time and can be deﬁned to include temporal start and end
points. Continuants can be further sub-divided into those physi-
cal objects that exist independent from other entities – indepen-
dent continuants (e.g., organs, tissues, cells, molecules, etc.), and
entities that depend on physical objects for their existence –
dependent continuants (e.g., the color red, the investigator role,
the ribonuclease molecular function). The OBI (http://purl.obo-
foundry.org/obo/obi/) builds upon BFO, extending the core struc-
ture by describing those entities that are speciﬁc to the
biomedical research domain. For example, occurrent is extended
to include subtypes of various process like biomaterial transfor-
mation, assay and data transformation; independent continuant
is extended to include biomaterial and instrument; dependent
continuant is extended to include investigator role, analyte role
and evaluant role. Both BFO and OBI have been built using a
strict is_a hierarchy of type/subtype relations and are compliance
with the principles for ontology development best practices pro-
mulgated by the OBO Foundry (http://www.obofoundry.org/
crit.shtml).
In order to determine if the structure of these ontologies could
be used to build a database that could support the management
of a wide range of data derived from clinical and translational re-
search studies, we extracted the core structure of the OBI exten-
sion of the BFO and developed a conceptualization of the core
components as a starting point for data modeling (Fig. 1A). The
central component of the core conceptual model is the Event ta-
ble, which includes descriptions of the actual events that hap-
pened during the study. These actual events may or may not be
planned. A planned event is a realization of Procedure Speciﬁca-
tion; this separation allows for situations in which the actual
event deviates from what was planned, including protocol devia-
tions and adverse events of critical importance to the clinical re-
search domain. Each event may also include one or more objects
that play deﬁned input and output roles. Each event also occurs
in a speciﬁed time context. And ﬁnally, each event occurs in the
context of a speciﬁc study that describes the actual realization
of a study design.
Fig. 1. OBX conceptual model representation. (1A) The schematic representation of the OBX core conceptual model showing high level concepts of Study Design, Study,
Independent Continuant (Object), Event, Dependent Continuant (Quality, Value, or Result) and Context (for each event). (1B) UML model for the Independent Continuant
Object. Human subject, Population (grouping of human subject), Animal Subject, Biological Sample (from human or animal subject), Compound, Site, Instrument, and
Software are all speciﬁc objects modeled in OBX. A complete UML representation of the resulting OBX conceptual model with cardinality restrictions can be found at http://
pathcuric1.swmed.edu/Research/scheuermann/OBX.html.
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for representing information about particular entities that need to
be described in the clinical research database component of Imm-
Port and how they relate to each other in subtype tables. (N.B. For
the sake of clarity, we use the term ‘‘universal entity” to describe
the classes of things in reality, ‘‘particular” to describe the speciﬁc
member of that class, ‘‘data entity” to describe the information
artifact in the conceptual model about the universal entity, and
‘‘data instance” to describe the information artifact value about
the particular member.) Again, we relied on OBI/BFO ontology de-
sign principles to capture the speciﬁc distinctions between the dif-
ferent entities.The following class types and subtypes have been modeled in
this way:
 Object – population, population arm, human subject, animal
subject, biological sample, compound, complex compound, soft-
ware, instrument, site (Fig. 1B).
 Biomaterial transformation – substance merging, device inter-
vention, surgery intervention, biosampling process, environ-
ment exposure process (Fig. 2).
 Assay – subject assessment, lab test, questionnaire, medical his-
tory taking, ECG (Fig. 3).
Fig. 2. Biomaterial transformation in OBX Model. UML model of the OBX biomaterial transformation class (2A) and a comparison of the Intervention domain of the CDISC-
SDTM with the biomaterial transformation component of the OBX model (2B). The arrow illustrates that the three Intervention classes – Concomitant Medications, Exposure
and Substance Use – in CDISC_STDM map to one Substance Merge class in OBX.
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outcome measure determination process, baseline characteris-
tic designation process, protocol deviation determination
(Fig. 4).
In each case, the subtype tables contain attributes that are spe-
ciﬁc to the given subtype. In some cases we have made practical
decisions to directly include data entities as attributes within ta-
bles in order to optimize database performance even though they
could be indirectly linked through table joining procedures. For
example, the Human Subject class contains attributes about pheno-
typic qualities of this particular entity, such as age and gender; it
also contains the information about country of birth, which is an-
other independent continuant. While these data entities could be
represented in separate dependent continuant and independent
continuant tables, we chose to include them as attributes in the
Human Subject table because they are so commonly linked withsubject participants in clinical and translational research. The
drawback to this approach is that the speciﬁc relations between
the subject class of the table and the associated attributes cannot
be easily represented in traditional object-oriented database ta-
bles, and must be inferred during downstream analytical
processing.
2.2. Biomaterial transformation
The process of biomaterial transformation, which is deﬁned as
events with one or more biomaterials as inputs and outputs, is dif-
ferentiated into merging, biosampling and transformation sub-
types in OBX (Fig. 2A). One example of an important merging
type of event is substance intervention (Substance Merging Bioma-
terial Transformation), whose description includes details about the
type of compound included, and the formulation, dose and route of
delivery used. In the case of Biosampling Process (e.g., blood draw or
Fig. 3. Assay in OBXModel. UML model of the OBX Assay class (2A) and a comparison of the Findings domain of the CDISC-SDTMwith the Assay component of the OBX model
(2B). PG, pharmacokinetics; MB, microbiology; QS, questionnaire; and InclExcl, inclusion/exclusion.
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Fig. 4. Data transformation in OBX Model. UMLmodel of the OBX data transformation class (4A) and a comparison of the Findings and the Events domains of the CDISC-SDTM
with the assay and the data transformation component of the OBX model (2B). PG, pharmacokinetics; MB, microbiology; QS, questionnaire; InclExcl, inclusion/exclusion; AE,
adverse event; Disp, disposition; and Devi, deviation.
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speciﬁed in the conceptual model. The Substance Biomaterial Trans-
formation (e.g., incubation of a specimen) describes the transfor-
mation from one biomaterial to another biomaterial. In this way,
a wide variety of different events can be deﬁned by describing
the event type, the input and output continuants and the roles that
they play in the process.
We compared the OBX approach to the data representation ap-
proaches in CDISC. The Study Data Tabulation Model (SDTM) is one
of the data standards developed by CDISC, which has been adoptedby the US Food and Drug Administration (FDA) to be the standard
format for clinical trial data to be submitted to the FDA. In SDTM,
observations collected during the study are divided into three clas-
ses: Interventions, Events, and Findings. Interventions class cap-
tures investigational treatments and is further divided into three
domains (Fig. 2B): Concomitant Medications (ConMeds), Exposure,
and Substance Use (Subst Use).
The OBX model places CDISC-SDTM Interventions class under
Biomaterial Transformation given that both the input and output in
the Interventions class are biomaterials. The inputs for Concomitant
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and the substances. The substances taken by the subject are called
concomitant medications, investigational drugs or self-adminis-
tered substances for Concomitant Medications, Exposure or Sub-
stance Use, respectively. The outputs of these interventional
processes are also subjects of the study. However, instead of using
three different domains to represent essentially the same process
as in CDISC-SDTM, OBX recognizes that the difference between Con-
comitant Medications, Exposure, and Substance Use is the role that
the substance plays in this Substance Merging Biomaterial Transfor-
mation (see Fig. 2A). By adding a Compound Role attribute, the Sub-
stance Merging Biomaterial Transformation class encompasses the
information that is captured in all three SDTM interventional
domains.
2.3. Assay
The assay process is deﬁned in OBI as events with one or more
biomaterials as inputs and data as outputs (http://obi-ontol-
ogy.org/page/Main_Page). In OBX, the Assay class is differentiated
into Subject Assessment, Lab Test, ECG, Adverse Event, and Subject
Inclusion/Exclusion classes (Fig. 3).
Subject Assessment and Lab Test differ in that lab tests involves a
specimen (biosample) as input and frequently utilize reagents for
measurement purposes (substance or compound chemicals)
whereas assessments involve a subject participant as input and
do not typically utilize reagents. Physical Exam, Medical History,
Family History and Questionnaire are examples of different types
of assessments. By using the ‘‘assessment type” or the ‘‘lab test
type” attribute, assessment or lab tests that are speciﬁc for certain
studies (e.g., atopic dermatitis skin assessment) can be captured by
OBX. Hematology, Urine Test and Pregnancy Test are examples of
types of Lab Test. ECG is captured as a special type of assessment
since it involves attributes such as lead position and baseline ﬂag
that are quite different from other types of assessment.
The OBX conceptual model puts the CDISC-SDTM Findings do-
main under Assay given that the input of the Findings domain is
biomaterial and the output is data. The SDTM pharmacokinetics,
lab test and microbiology domains correspond to the Lab Test in
OBX whereas the SDTM Vital Signs, Physical Exam and Question-
naire map to Assessment in OBX. The SDTM inclusion/exclusion
class maps to Subject Inclusion/Exclusion class in OBX. In addition,
part of the SDTM Event domain, including adverse events, medical
history and clinical event, maps to the Assay domain in OBX (see
Fig. 3B). The rest of the Event domain in CDISC-SDTM including
study deviation and disposition map to the Data Transformation do-
main in OBX (see Fig. 4B).
2.4. Data transformation
The process of data transformation is an event in which both the
input and the output are data (Fig. 4). The Research Data Analysis
(e.g., microarray data analysis) process is a good example of data
transformation. Starting from Primary Result (e.g., .cel ﬁle which
contains the ﬂuorescent intensity of all the spots on the slide) col-
lected in the study, the study investigator may get a set of Derived
Result (e.g., a list of differentially expressed genes) after certain
steps of data processing, or draw conclusions from the study. Base-
line Measure Process, deﬁned as a data transformation process the
output of which is a table of demographic and baseline data for
the entire trial population and for each arm or comparison group
(www.clinicaltrials.gov, [12]), captures basic statistical measures
of the study population such as average age and gender propor-
tions using the demographic data as input. Outcome Measure Pro-
cess, deﬁned as a data transformation process whose output is a
table of values for each of the outcome measures by arm(www.clinicaltrials.gov, [12]), speciﬁcally captures study result
for each study arm using data collected about individual enrolled
in each arm as input. The Diagnosis Process uses available data col-
lected as input for the decision making process. The Protocol Devi-
ation (part of the Event domain in CDISC-SDTM) and the Study
Reported Premature Termination classes start by looking at available
recorded data and give the output as protocol deviation or early
termination, respectively.
2.5. Composite process
Even though OBX differentiates clinical processes as biomaterial
transformation, assay and data transformation, certain clinical
events are combinations of these three basic process types
(Fig. 5). For example, a clinical encounter (e.g., visit) may be com-
posed of a blood draw (a biomaterial transformation), a lab test
(assay) and a diagnosis (data transformation), or a data analysis
pipeline may involve several steps of data transformation. We call
these ‘‘composite process” or ‘‘complex event”. OBX currently in-
cludes two approaches for grouping events. The ﬁrst is the Actual
Visit, which groups events occurring for a single subject in a single
clinical encounter. An actual visit may reference a planned visit
and will reference actual events. If the actual visit is associated
with a planned visit then the actual events will often correspond
to the planned events of the planned visit. The second approach
is the Panel of Events. A panel of events speciﬁes a set of associated
events and allows multiple instances of that event set to be associ-
ated with actual events. An example of an event panel is rush
immunotherapy with subject assessments in which each event
set consists of a serious of immunotherapy exposures followed
by two subject assessments checking for adverse events. The entire
panel consists of a Sequence of Events set. There would be as many
event sets in a subject’s rush immunotherapy event panel as there
were immunotherapy exposures.2.6. Study design
The set of classes comprising a study design allows representa-
tion of many elements of a study’s protocol in OBX (Fig. 6). The
Study Design class provides attributes describing the study includ-
ing the study title, study type (observational or interventional), a
summary of the study, principal investigator, condition of focus,
planned study outcomes, etc. Two subclasses of the Study Design
class, Observational Study Design and Interventional Study Design,
augment the Study Design class with descriptive attributes that
are speciﬁc to observational or interventional studies. Many of
the attributes in the study design classes correspond to the study
attributes described in the document Protocol Data Element Deﬁ-
nitions (DRAFT) available at ClinicalTrials.gov [13]. For study Arm
and Period, we have incorporated the concepts from the CDISC-
SDTM and the BRIDG model. An arm is a grouping of study subjects
that either share the same characteristics (e.g., case or control for
observational study) or get the same treatments (e.g., interven-
tional or placebo in interventional study). A period marks a section
of the study time line having a speciﬁc purpose in the course of the
study, e.g., screening, treatment, or follow-up. A study time line
has at least one period. If a study has only one period as is the case
with many observational studies, then the name of the period is
‘‘entire study”. The Visit class is used to construct a study’s sche-
dule of events. It links together Arm, Period and Planned Event clas-
ses and speciﬁes the time window within which a set of planned
events occurs. The Event Plan class can be further categorized into
the Biomaterial Transformation Plan (e.g., blood draw plan), Assay
Plan (e.g., lab test plan or assessment plan) and the Data Transfor-
mation Plan (e.g., statistical analysis plan). In Clinical studies, an ac-
Fig. 5. Composite Process in OBX Model. OBX captures the composite process (sequence of event) through a panel of event (Panel of Events) and the order of the events
(Sequence of Events).
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corded during the course of a study may or may not correspond
to an Event Plan.
2.7. Database schema
The physical implementation of the conceptual model is the
database schema. The database implementation of OBX allows
the widely varied contents of the diverse clinical data to be loaded
and retrieved for display. The database schema was ontologically
derived, but the process of ﬁlling the database was not ontology
driven per se; that is, the loading process was not looking for con-
ceptual matches between the contents of a study and the contents
of an ontology. Rather, it was required to allow easy mapping of
syntactic structure of the study data sets into the syntactic struc-
ture of the database schema.
A major characteristic of the growing collection of clinical stud-
ies is that the number of deﬁned data entities in the study data sets
tends to grow without bounds as studies are added to the collec-
tion. Every study is likely to describe its own set of assessments,
for example. Thus a challenge facing the database was to ﬁnd a
mechanism for managing the proliferation of data entities in the
study data sets without proliferating the tables in the database
schema by using a one to one match to the different data entities
in the study data sets.
The data entity management is achieved by partitioning the
OBX conceptual model into common and study speciﬁc parts:
 Data entities that represent common components of all studies
such as visit plan, subject demographics, or adverse events are
modeled as data entities with a well-deﬁned ﬁnite set of attri-
butes (row model). This modeling takes advantage of the emer-
gence of reporting standards (e.g., CDISC) for common events
such as adverse events or ECGs. Data entities such as subject assessments and lab test panels that
are study speciﬁc, or whose numbers of attributes vary from
study to study (such as Vital Signs where the same assessment
canbe called Physical Exam inone study andVital Sign in another
study) are modeled using the data Entity-Attribute-Value (EAV)
approach.
An EAV model may be thought of as a 90 rotation of the row
model used by classic relational database tables. In a row model,
each row corresponds to data entities about a particular of a uni-
versal entity class, each column corresponds to the representation
of an attribute of the entity and the cells formed by the intersection
of columns and rows contain entity attribute values corresponding
to data instances about those particular entities. In an EAV model,
one row represents a cell from the row model in which the value is
tagged with entity class and attribute class labels. In any data in-
stance of a row model, the number of attributes and the identity
of the attributes of an entity are ﬁxed. The EAV model allows an
indeﬁnite number of data instances of attributes of any type to
be associated with a data entity and also allows many different
data entities to be represented in the same form. Note that an
EAV model is not equivalent to an RDF triples data store. Entity,
attribute, and value records tend to contain information about a
particular quality of a particular entity, which is not equivalent
to subject, predicate, and object components of an RDF triple.
The EAV model is more constrained in its expressivity. As men-
tioned above, a primary goal for developing the database schema
for the ImmPort clinical data repository has been to control the
multiplication of modeled data entities needed to represent the
different universal classes of entities; therefore, we used both the
row model and the EAV model to balance the ﬂexibility needed
and the performance desired.
A pure EAV triple store containing thousand of assertion types of
data entities would be just as unfathomable as a database schema
Fig. 6. Study Design in OBX Model. OBX captures the study type, inclusion exclusion criteria, study descriptions, location of the study, study Arm, study period, visit and the
planned events for each visit.
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approach to making an EAV model usable involves the following
modiﬁcations to a pure triple store:
 The EAV model is partitioned so that assays (lab tests and
subject assessments), biomaterial transformations (such as
drug interventions, biological material sampling, and
environmental exposure), and data transformations (includ-
ing data derived from lab tests and assessments) each
have their own set of tables. In any area of the EAV model
you know the type of data entities with which you are
dealing. The scope of an EAV row is expanded beyond a single attribute
value pair by including attributes that can be optionally associ-
ated with the main attribute of the row. So an EAV row for an
assessment component will contain not only the component
name (the attribute identiﬁer) and result value, but also associ-
ated units of measure, results categories and so forth. The set of
additional associated attributes provided for a single EAV row
dependsonthepartitionof theEAVmodel inwhichtherowexists.
 The rows of the EAV model that constitute a data entity’s attri-
butes are identiﬁed by grouping tables. For example, the Assess-
ment Panel table groups the individual attributes and values
that make up an assessment, and the Lab Test Panel groups all
Y. Megan Kong et al. / Journal of Biomedical Informatics 44 (2011) 48–58 57the lab tests that are normally composed into panels. These
grouping tables provide a single row identifying a data entity in
the EAV model and also are used to associate a data entity with
the study time line so that time line references do not have to
be pushed down to the individual attribute level.
 The model provides support for describing complex events such
as a rush immunotherapy regimen, and for creating identiﬁed
groupings of the lower level intervention and assessment
events which comprise the complex event.
In practice the team working with loading the ImmPort reposi-
tory has found that mapping many different types of data entities
into the multi-level EAV database schema is a straightforward pro-
cess. So the unbounded extensibility of the EAV model is working
in practice to control the proliferation of entities in the ImmPort
repository while retaining easy access to entity identities provided
by the single row entity identiﬁers in the grouping tables.3. Discussion
The Ontology-Based eXtensible (OBX) conceptual model was
developed to support the implementation of the clinical research
database component of the ImmPort system. ImmPort has used
available standards such as CDISC-SDTM and BRIDG to guide
development of the clinical study aspects of the OBX conceptual
model. Certain speciﬁc parts of these standards, such as the SDTM
standard for modeling a study time line using study days, were
adopted as standards for the ImmPort repository. In addition, these
standards have provided critical guidance in deﬁning the scope of
data elements to incorporate into the OBX model of biomedical
investigations and in deﬁning the attributes of these data ele-
ments. For example, the SDTM Adverse Event domain provided
most of the descriptive attributes of adverse events used for the
OBX adverse event domain.
The OBX model has now been implemented as the database for
capturing clinical research data in ImmPort. We have successfully
mapped components of a variety of clinical studies from the Atopic
Dermatitis Vaccinia Network, Immune Modeling Centers and the
Immune Tolerance Network into this model representation. The
complexity of these study ranges from observational studies, to
phase II multi-arm interventional studies. Based on this exercise,
we have reﬁned the conceptual model to ensure that we can not
only describe information about the basic entity classes in a clini-
cal study, e.g., human subjects, biosamples, assays, assessments
and assessment results, but also the more complex components
of a clinical study, e.g., protocol deviations, adverse events, study
arm speciﬁcations and composite events like the clinical visit.
The fact that a variety of studies from different sites have been suc-
cessfully loaded into a database based on OBX supports the idea
that the approach achieved the level of extensibility and interoper-
ability sought for the ImmPort system. We have also successfully
implemented clinical data user interfaces to allow users to view,
query and download data from ImmPort (www.immport.org).3.1. Characteristics of the OBX model
During the reﬁnement process, several advantages of the OBX
approach have been noted. The relatively simple structure of
OBX has made it relatively easy to add new class tables to the data-
base schema without disrupting the pre-existing structure. The
logical framework used provides a consistent mechanism for link-
ing component data entities together. It is relatively easy to re-use
data entity tables as needed in generating primary key-foreign key
relationships. The fact the OBX is based on the logical framework of
BFO/OBI allows for its obvious integration with ontology term useas values for speciﬁc data elements in the database record in-
stances in the future.
OBX also allows for the integration of clinical data (CRF data)
and mechanistic experiment data. An experiment is a type of Assay
(input is biomaterial and output is data). Speciﬁcally, most labora-
tory experiment would correspond to a Lab Test because of the use
of reagents in the study of specimens. In this way, OBX can put the
experiment inside the clinical study on the study time line, which
then greatly facilitates the clinical data analysis.
3.2. OBX model and BRIDG model
The purpose of OBX is to archive completed clinical studies and
to facilitate data integration and data re-use. Therefore the patient
management information found in BRIDG (http://bridgmodel.org/)
designed to monitor ongoing clinical trials, such as HealthCarePro-
vider, HealthCareFacility, LegalSponsor, Resource Provider, Over-
sightAuthority and RegulatoryAuthority, is considered to be
outside the scope of OBX. In the process of OBX development, we
made the clear distinction between describing a process and the
result of the process. We believe capturing the process is important
for recapitulating the process and for understanding the results.
BRIDG, however, tends to focus on the research result but not
the process that gives rise to the result. For example, in BRIDG,
the class PerformedClinicalResult is derived from of PerformedOb-
servationResult class. However, the actual clinical process (maybe
a lab test), which gives rise to the PerformedClinicalResult or the
PerformedObservationResult is not captured. Similarly, the BRIDG
PerformedDiagnosis class only captures the ﬁnal diagnosis, but
the process through which the investigator makes that speciﬁc
diagnosis is not recorded, i.e., the input parameters for this data
transformation process are not captured.
3.3. Implementation of the OBX model
We have recently completed a physical database schema based
on this model, which is made freely available at www.imm-
port.org. We are now in the process of preparing a complete docu-
mentation of the database schema that includes a description of
the design principles detailed here, deﬁnitions for each of the data
element classes, suggested sources of value sets for use in populat-
ing speciﬁc database records based on standard vocabularies or
ontologies, and an implementation guide.
The OBX database schema is now being used to support the cap-
ture, managements, query of a wide range of different clinical re-
search studies in the ImmPort system for the National Institute
of Allergy and Infectious Disease. Databases built upon the OBX
framework could be implemented more extensively at academic
health centers focused on clinical and translational research,
including those institutions that are part of the NIH-funded Clinical
and Translational Science Award (CTSA) program. Indeed, the
North and Central Texas Clinical and Translational Sciences Insti-
tute is in the process of evaluating the OBX model to store data de-
rived from its clinical and translational research programs. Having
said this, many of the CTSA and other institutions conducting these
kinds of research programs are in the process of developing their
own database infrastructures based on other common conceptual
models (e.g., BRIDG) or their own home-brewed approaches. Ide-
ally, one would want to compare the different models to determine
whether any provide signiﬁcant advantages over the others, per-
haps by comparing the results of usage metrics for data repre-
sented in each [14]. However, it would take a great deal of effort
to perform such a comprehensive comparative analysis. In addi-
tion, the fact that many extant systems have already been built
upon other models and that regulatory agencies (e.g., the FDA)
have already proposed the adoption of speciﬁc models add to the
58 Y. Megan Kong et al. / Journal of Biomedical Informatics 44 (2011) 48–58complexity of the outcome of any such comparison. Thus, the most
practical stance is that OBX can be considered as an alternative
model for capturing managing and using clinical and translational
research data. Groups considering the implementation of database
systems will need to evaluate the alternative strategies based on
the theoretical underpinnings of the different approaches, their
speciﬁc needs, and their existing infrastructure. But one of the
advantages of adoption of OBX by other organization interested
in managing clinical research data is that it would support data
sharing, system interoperability and semantic query of data con-
tent from the Immunology Database and Analysis Portal.
3.4. Future directions
In order to extend this initial modeling work into a useful arti-
fact in support of clinical research data management and interop-
erability data sharing, we are in the process of combining the UML
model with a data dictionary and an implementation guide, such
that sufﬁcient information is provided for its use in database devel-
opment. We are also integrating a vocabulary service component,
through the NCBO BioPortal (http://www.bioontology.org/) or the
EBI Ontology Lookup Service (www.ebi.ac.uk/ontology-lookup/),
based on relevant OBO Foundry ontologies to provide the preferred
value sets for the data elements described in the OBX model and to
support the power of reasoning provided by the use of ontologies
as the source for the structured vocabularies.
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